1.1Epinephrine bitartrate in solution
The bitartrate salt dissolves in an acidic aqueous vehicle. The weighed salt mass accounts for the bitartrate counterion when setting the epinephrine concentration.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The bitartrate salt dissolves in an acidic aqueous vehicle. The weighed salt mass accounts for the bitartrate counterion when setting the epinephrine concentration.
The formulation process adds the weighed free base to an aqueous vehicle acidified with hydrochloric acid. Protonation of the amine increases aqueous solubility and produces dissolved epinephrine with chloride as the counterion.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
No entries.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
An epinephrine malonate salt in crystalline form.A · US 10,995,059 B2 · claim 1
In a preferred embodiment, the polymorphic crystalline epinephrine malonate has an x-ray powder diffraction pattern identified in FIG. 1.B · US 2023/0086578 A1 · ¶ 4
An empty cell means only that no passage was reproduced there.
The pharmaceutical composition can be suitable for oral, rectal, intragastrical, topical, intracranial, intranasal, and parenteral administration.A · US 10,995,059 B2 · ¶ 5
In certain embodiments, the pharmaceutical composition can disintegrate in less than or equal to 30 seconds.A · US 10,995,059 B2 · ¶ 5
The pharmaceutical composition can be suitable for oral, rectal, intragastrical, topical, intracranial, intranasal, and parenteral administration.B · US 2023/0086578 A1 · ¶ 5
In certain embodiments, the pharmaceutical composition can disintegrate in less than or equal to 30 seconds.B · US 2023/0086578 A1 · ¶ 5
patent.fyi, US 2026/0355132 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355132/, SHA-256 95e1a9d59fdf47e9879fce2fde947a2a59935282054e10d7f264e1294849e263